Progression-free Survival 96% in CLL With Ibrutinib – Medscape
Progression-free Survival 96% in CLL With IbrutinibMedscapeJennifer Brown, MD, assistant professor in the Department of Medicine at Harvard Medical School in Cambridge, Massachusetts, presented interim data on ibrutinib in combination with bendamustine…